Icariin Inhibits RANKL-induced Osteoclastogenesis Via Modulation of the NF-κB and MAPK Signaling Pathways.

Qiang Xu,Guiping Chen,Xuqiang Liu,Min Dai,Bin Zhang

DOI: https://doi.org/10.1016/j.bbrc.2018.11.201

IF: 3.1

2019-01-01

Biochemical and Biophysical Research Communications

Abstract:The receptor activator of nuclear factor-kappa B (NF-kappa B) ligand (RANKL)-RANK regulatory axis is a major regulator of osteoclast differentiation and activation. Icariin, a flavonol glycoside isolated from the Epimedium herb, has been reported to prevents bone loss in ovariectomized mice and inhibits wear particle-induced osteolysis. However, the molecular mechanism through which icariin inhibits RANKL-induced osteoclastogenesis has not been fully understood. Therefore, we aimed to investigate the effects of icariin on RANKL-induced osteoclastogenesis and to elucidate the mechanism underlying this effect. Our results showed that RANKL-induced osteoclastogenesis was inhibited by icariin in bone marrow macrophages (BMMs) and RAW264.7 cells, and that this effect was due to suppression of NF-kappa B and mitogen-activated protein kinase (MAPK) activation. In addition, icariin inhibited F-actin ring formation and attenuated the bone resorption ability of mature osteoclasts. Collectively, our results indicate that icariin may be a promising potential candidate for the treatment of osteolytic diseases such as osteoporosis. Moreover, our findings lay the foundation for understanding and intervening in osteoclast-related diseases at the molecular level. (C) 2018 Elsevier Inc. All rights reserved.